Compare Devon Energy Corp (DVN) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Revvity Inc — how do they compare? Devon Energy Corp trades at $48.33 (market cap $53.81B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: Devon Energy Corp is far larger — about 3.2× Revvity Inc's market cap, and Devon Energy Corp pays the higher dividend (2.62%). Which is the better fit depends on your goals — on Pluang, investors hold Devon Energy Corp for 136 Days and Revvity Inc for 12 Days on average.
| DVN | RVTY | |
|---|---|---|
Market Cap | $53.81B | $16.98B |
Volume | 11,556,740 | 1,456,900 |
Sector | Energy | Health |
52-Week High | $52.07 | $157.36 |
52-Week Low | $31.74 | $82.26 |
Typical Hold Time | 136 Days | 12 Days |
Enterprise Value | $64.55B | $19.30B |
Dividend Yield | 2.62% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $48.26, up 0.79% with a bullish technical outlook. The stock shows strong fundamentals with a P/E of 10.63 and net margin of 16.67%, supported by recent earnings beats. Analyst consensus is strongly bullish with a $62.53 price target, representing 30% upside potential. Recent news highlights activist investor pressure for strategic alternatives including potential sale, while BP shows interest in acquiring Eagle Ford assets.
DVN presents compelling value with attractive valuation metrics and solid profitability. Key opportunities include potential asset sales and Permian Basin strength, while risks involve oil price volatility and execution of strategic initiatives. The stock's current valuation discount to analyst targets suggests significant upside if operational improvements materialize.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
